Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Practice Guidelines
    • Featured Practice Guidelines
    • Antibiotic use in...

    Antibiotic use in catheter-associated UTI: NICE Guidelines

    Written by Vinay Singh singh Published On 2018-12-05T19:00:30+05:30  |  Updated On 9 Aug 2021 5:01 PM IST

    NICE has released guidelines on antimicrobial prescribing strategy for catheter-associated urinary tract infection(UTI) in children, young people, and adults.


    A catheter is a tube that is inserted in the bladder to drain urine. It can let bacteria into the body, and this can lead to a bladder or kidney infection (urinary tract infection, or UTI). Bacteria are often found in the urine of people with catheters.


    Recommendations


    The guidelines include recommendations on:

    1.1 Managing catheter-associated urinary tract infection

    1.2 Self-care

    1.3 Choice of antibiotic

    1.4 Preventing catheter-associated urinary tract infections






    1.1 Managing catheter-associated urinary tract infection1.1.1 Be aware that:


    • a catheter-associated urinary tract infection (UTI) is an asymptomatic infection of the bladder or kidneys in a person with a urinary catheter

    • the longer a catheter is in place, the more likely bacteria will be found in the urine; after 1 month nearly all people have bacteriuria

    • antibiotic treatment is not routinely needed for asymptomatic bacteriuria in people with a catheter.



    1.1.2 Give advice about managing symptoms with self-care to all people with catheter-associated UTI.

    Treatment


    1.1.3 Consider removing or, if this cannot be done, changing the catheter as soon as possible in people with a catheter-associated UTI if it has been in place for more than 7 days. Do not allow catheter removal or change to delay antibiotic treatment.

    1.1.4 Obtain a urine sample before antibiotics are taken. Take the sample from the catheter, via a sampling port is provided, and use an aseptic technique (in line with the NICE guideline on healthcare-associated infections).


    • If the catheter has been changed, obtain the sample from the new catheter.

    • If the catheter has been removed, obtain a midstream specimen of urine.



    1.1.5 Send the urine sample for culture and susceptibility testing, noting a suspected catheter-associated infection and an antibiotic prescribed.

    1.1.6 Offer an antibiotic (see the recommendations on choice of antibiotic) to people with catheter-associated UTI. Take account of:


    • the severity of symptoms

    • the risk of developing complications, which is higher in people with known or suspected structural or functional abnormality of the genitourinary tract, or immunosuppression

    • previous urine culture and susceptibility results

    • previous antibiotic use, which may have led to resistant bacteria.



    1.1.7 When urine culture and susceptibility results are available:


    • review the choice of antibiotic and

    • change the antibiotic according to susceptibility results if the bacteria are resistant, using narrow-spectrum antibiotics wherever possible.





    Advice when an antibiotic prescription is given


    1.1.8 When an antibiotic is given, as well as the general advice on self-care, give advice about:


    • possible adverse effects of antibiotics, particularly diarrhea and nausea

    • seeking medical help if:


      • symptoms worsen at any time or

      • symptoms do not start to improve within 48 hours of taking the antibiotic or

      • the person becomes systemically very unwell.







    Reassessment


    1.1.9 Reassess people with catheter-associated UTI if symptoms worsen at any time, or do not start to improve within 48 hours of taking the antibiotic, taking account of:


    • other possible diagnoses

    • any symptoms or signs suggesting a more serious illness or condition, such as sepsis

    • previous antibiotic use, which may have led to resistant bacteria.





    Referral and seeking specialist advice


    1.1.10 Refer people with catheter-associated UTI to the hospital if they have any symptoms or signs suggesting a more serious illness or condition (for example, sepsis).

    1.1.11 Consider referring or seeking specialist advice for people with catheter-associated UTI if they:


    • are significantly dehydrated or unable to take oral fluids and medicines or

    • are pregnant or

    • have a higher risk of developing complications (for example, people with a known or suspected structural or functional abnormality of the genitourinary tract, or underlying disease [such as diabetes or immunosuppression]) or

    • have recurrent catheter-associated UTIs or

    • have bacteria that are resistant to oral antibiotics.






    1.2 Self-care


    1.2.1 Advise people with catheter-associated UTI about using paracetamol for pain.


    1.2.2 Advise people with catheter-associated UTI about drinking enough fluids to avoid dehydration.


    1.3 Choice of antibiotic



    1.3.1 When prescribing an antibiotic for catheter-associated UTI, take account of local antimicrobial resistance data and:





    • follow table 1 for non-pregnant women and men aged 16 years and over

    • follow table 2 for pregnant women aged 12 years and over

    • follow table 3 for children and young people under 16 years.



    1.3.2 Give oral antibiotics first line if the person can take oral medicines, and the severity of their condition does not require intravenous antibiotics.


    1.3.3 Review intravenous antibiotics by 48 hours and consider stepping down to oral antibiotics where possible.




    Table 1 Antibiotics for non-pregnant women and men aged 16 years and over


























































































    AntibioticDosage and course length
    First-choice oral antibiotic if no upper UTI symptoms
    Nitrofurantoin – if eGFR ≥45 ml/minute3,4100 mg modified-release twice a day for 7 days
    Trimethoprim – if a low risk of resistance5200 mg twice a day for 7 days
    Amoxicillin (only if culture results available and susceptible)500 mg three times a day for 7 days
    Second-choice oral antibiotic if no upper UTI symptoms (when first-choice not suitable) 2
    Pivmecillinam (a penicillin)4400 mg initial dose, then 200 mg three times a day for a total of 7 days
    First-choice oral antibiotic if upper UTI symptoms
    Cefalexin500 mg twice or three times a day (up to 1 to 1.5 g three or four times a day for severe infections) for 7 to 10 days
    Co-amoxiclav (only if culture results available and susceptible)500/125 mg three times a day for 7 to 10 days
    Trimethoprim (only if culture results available and susceptible)200 mg twice a day for 14 days
    Ciprofloxacin (consider safety issues6)500 mg twice a day for 7 days
    First-choice intravenous antibiotic (if vomiting, unable to take oral antibiotics or severely unwell). Antibiotics may be combined if susceptibility or sepsis a concern
    Co-amoxiclav (only in combination, unless culture results confirm susceptibility)1.2 g three times a day
    Cefuroxime750 mg to 1.5 g three or four times a day
    Ceftriaxone1 to 2 g once a day
    Ciprofloxacin (consider safety issues6)400 mg twice or three times a day
    GentamicinInitially 5 to 7 mg/kg once a day, subsequent doses adjusted according to serum gentamicin concentration8
    AmikacinInitially 15 mg/kg once a day (maximum per dose 1.5 g once a day), subsequent doses adjusted according to serum amikacin concentration (maximum 15 g per course)
    Second-choice intravenous antibiotic
    Consult local microbiologist
    Abbreviations: BNF, British national formulary; eGFR, estimated glomerular filtration rate; UTI, urinary tract infection.




    Table 2 Antibiotics for pregnant women aged 12 years and over

































    AntibioticDose and course length
    First-choice oral antibiotic
    Cefalexin500 mg twice or three times a day (up to 1 to 1.5 g three or four times a day for severe infections) for 7 to 10 days
    First-choice intravenous antibiotic (if vomiting, unable to take oral antibiotics, or severely unwell)
    Cefuroxime750 mg to 1.5 g three or four times a day
    Second-choice antibiotics or combining antibiotics if susceptibility or sepsis a concern
    Consult local microbiologist




    Table 3 Antibiotics for children and young people under 16 years






































































    AntibioticDosage and course length
    Children under 3 months
    Refer to pediatric specialist and treatment with intravenous antibiotics in line with the NICE guideline on fever in under 5s.
    Children aged 3 months and over
    First-choice oral antibiotics
    Trimethoprim – if the low risk of resistance3 to 5 months, 4 mg/kg (maximum 200 mg per dose) or 25 mg twice a day for 7 to 10 days

    6 months to 5 years, 4 mg/kg (maximum 200 mg per dose) or 50 mg twice a day for 7 to 10 days

    6 to 11 years, 4 mg/kg (maximum 200 mg per dose) or 100 mg twice a day for 7 to 10 days

    12 to 15 years, 200 mg twice a day for 7 to 10 days
    Amoxicillin (only if culture results available and susceptible)3 to 11 months, 125 mg three times a day for 7 to 10 days

    1 to 4 years, 250 mg three times a day for 7 to 10 days

    5 to 15 years, 500 mg three times a day for 7 to 10 days
    Cefalexin3 to 11 months, 12.5 mg/kg or 125 mg twice a day for 7 to 10 days (25 mg/kg two to four times a day [maximum 1 g per dose four times a day] for severe infections)

    1 to 4 years, 12.5 mg/kg twice a day or 125 mg three times a day for 7 to 10 days (25 mg/kg two to four times a day [maximum 1 g per dose four times a day] for severe infections)

    5 to 11 years, 12.5 mg/kg twice a day or 250 mg three times a day for 7 to 10 days (25 mg/kg two to four times a day [maximum 1 g per dose four times a day] for severe infections)

    12 to 15 years, 500 mg twice or three times a day (up to 1 to 1.5 g three or four times a day for severe infections) for 7 to 10 days
    Co-amoxiclav (only if culture results available and susceptible)3 to 11 months, 0.25 ml/kg of 125/31 suspension three times a day for 7 to 10 days (dose doubled in severe infection)

    1 to 5 years, 0.25 ml/kg of 125/31 suspension or 5 ml of 125/31 suspension three times a day for 7 to 10 days (dose doubled in severe infection)

    6 to 11 years, 0.15 ml/kg of 250/62 suspension or 5 ml of 250/62 suspension three times a day for 7 to 10 days (dose doubled in severe infection)

    12 to 15 years, 250/125 mg or 500/125 mg three times a day for 7 to 10 days
    First-choice intravenous antibiotics (if vomiting, unable to take oral antibiotics or severely unwell). Antibiotics may be combined if susceptibility or sepsis a concern
    Co-amoxiclav (only in combination unless culture results confirm susceptibility)3 months to 15 years, 30 mg/kg three times a day (maximum 1.2 g three times a day)
    Cefuroxime3 months to 15 years, 20 mg/kg three times a day (maximum 750 mg per dose); (50 to 60 mg/kg three or four times a day [maximum 1.5 g per dose] for severe infections)
    Ceftriaxone3 months to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day)

    9 to 11 years (50 kg and above), 1 to 2 g once a day

    12 to 15 years, 1 to 2 g once a day
    GentamicinInitially 7 mg/kg once a day, subsequent doses adjusted according to serum gentamicin concentration7
    AmikacinInitially 15 mg/kg once a day, subsequent doses adjusted according to serum amikacin concentration7
    Second-choice intravenous antibiotic
    Consult local microbiologist





    1.4 Preventing catheter-associated urinary tract infections




    • Do not routinely offer antibiotic prophylaxis to prevent catheter-associated UTIs in people with a short-term or a long-term (indwelling or intermittent) catheter.

    • Give advice about seeking medical help if symptoms of an acute UTI develop.


    For further reference log on to :

    https://www.nice.org.uk/guidance/ng113/chapter/Recommendations



    catheterchildrenintravenousmenNICEoralpregnantresistanceurinary tract infectionUTIwomenYoung
    Source : With inputs from NICE

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Vinay Singh singh
    Vinay Singh singh
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok